Current and past menstrual status is an important determinant of femoral neck geometry in exercising women.

Rebecca J. Mallinson,N. Williams,J. Gibbs,K. Koehler,H. Allaway,Emily A Southmayd,M. D. De Souza

DOI: https://doi.org/10.1016/j.bone.2016.01.030

IF: 4.626

2016-07-01

Bone

Abstract:

What problem does this paper attempt to address?

CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

K. Excoffon,M. A. Abou Alaiwa,N. Gansemer,P. Sinn,Drake C. Bouzek,B. Steines,David D. Dickey,J. Engelhardt,M. Welsh,Xiaopeng Li,J. Zabner,D. Schaffer,John R. Weinstein,Ziying Yan,Viral S. Shah,Linda S. Powers,L. Ostedgaard,D. Stoltz,J. Bergen

DOI: https://doi.org/10.1172/jci.insight.88728

IF: 9.4958

2016-09-08

JCI Insight

Abstract:The physiological components that contribute to cystic fibrosis (CF) lung disease are steadily being elucidated. Gene therapy could potentially correct these defects. CFTR-null pigs provide a relevant model to test gene therapy vectors. Using an in vivo selection strategy that amplifies successful capsids by replicating their genomes with helper adenovirus coinfection, we selected an adeno-associated virus (AAV) with tropism for pig airway epithelia. The evolved capsid, termed AAV2H22, is based on AAV2 with 5 point mutations that result in a 240-fold increased infection efficiency. In contrast to AAV2, AAV2H22 binds specifically to pig airway epithelia and is less reliant on heparan sulfate for transduction. We administer AAV2H22-CFTR expressing the CF transmembrane conductance regulator (CFTR) cDNA to the airways of CF pigs. The transduced airways expressed CFTR on ciliated and nonciliated cells, induced anion transport, and improved the airway surface liquid pH and bacterial killing. Most gene therapy studies to date focus solely on Cl- transport as the primary metric of phenotypic correction. Here, we describe a gene therapy experiment where we not only correct defective anion transport, but also restore bacterial killing in CFTR-null pig airways.

Biology,Medicine
WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

B. Qiu,D. Manzanares,X. Wang,Z. He,Y. Li,S. A,I. Lara-Sáez,W. Wang

DOI: https://doi.org/10.1016/s1569-1993(23)00280-1

IF: 5.527

2023-01-01

Journal of Cystic Fibrosis

Abstract:Objective: Currently there is no cure for cystic fibrosis (CF) disease and lung is the most affected organ [1Cooney A Gene. 2018 Nov; 9: 538Crossref Scopus (72) Google Scholar]. Gene replacement is a promising strategy to treat this disease. However, the two big challenges that have impeded its success are the absence of: (1) an efficient and safe gene delivery reagent to transfect the target cells, and (2) a stable plasmid that enables high and sustained CF transmembrane conductance regulator (CFTR) expression. Thus, the aim of this work is to develop a non-viral CFTR gene replacement system for lung CF disease to overcome these two challenges. Methods: A cationic highly branched poly(β-amino ester) (HPAE) polymer [2Zhou D Sci Adv. 2016 Jun; 6e160010Google Scholar] with high transfection efficiency was used as a non-viral gene delivery reagent complexed to a CpG-depleted CFTR plasmid with high and sustained CFTR expression and expected lower immune response to transfect CF lung epithelial cells in vitro. Results: By using the HPAE for CFTR gene delivery, similar gene expression and higher cell viability (~98%) than commercial transfection reagents such as Xfect™ (~77%) and Lipofectamine™ 3000 (~51%) were achieved after 48 hours. Moreover, around 2400% and 120% higher CFTR protein levels compared to healthy human lung epithelial cells were obtained after 48 hours and 7 days of transfection in CF lung epithelial cells, respectively. Conclusion: We developed a very promising HPAE/CFTR polyplex system as it is demonstrated that only 6–10% CFTR protein expression of healthy lung epithelial cells is enough to restore the ionic transport in CF lung epithelial cells [3Johnson L Nat Genet. 1992 Sep; 2: 21-25Crossref PubMed Scopus (382) Google Scholar]. In addition, a nebulization system for testing this HPAE/CFTR polyplex system in vivo by inhalation in mice is being currently developed. The expected results could potentially support the future use of this technology as a gene therapy for treating lung cystic fibrosis disease.
Expression of a Truncated Cystic Fibrosis Transmembrane Conductance Regulator with an AAV5-pseudotyped Vector in Primates

Anne C Fischer,Carolina I Smith,Liudmila Cebotaru,Xuemei Zhang,Frederic B Askin,Jerry Wright,Sandra E Guggino,Robert J Adams,Terence Flotte,William B Guggino

DOI: https://doi.org/10.1038/sj.mt.6300059

IF: 12.91

2007-01-01

Molecular Therapy

Abstract:Gene therapy using recombinant adeno-associated virus (rAAV2) vectors for cystic fibrosis has shown gene transfer and remarkable safety, yet indeterminate expression. A new construct has been characterized with a powerful exogenous promoter, the cytomegalovirus enhancer/chicken beta-actin promoter, driving a truncated CF transmembrane conductance regulator (CFTR), pseudotyped in an AAV5 viral coat. Our goal is to demonstrate that airway delivery of a pseudotyped rAAV5 vector results in gene transfer as well as expression in non-human primates. Aerosolized pseudotyped rAAV5-DeltaCFTR or rAAV5-GFP (green fluorescent protein) genes were delivered to four and six lungs, respectively. The pseudotyped rAAV5 vector did result in GFP gene transfer (1.005x10(6) copies/mug DNA on average) and quantifiable gene expression. Microscopy confirmed protein expression in airway epithelium. Similarly, the vector also resulted in vector-specific CFTR DNA (1.24x10(5) copies/microg) and mRNA expression. Immunoprecipitation and (32)P phosphoimaging were used to demonstrate CFTR protein expression, as qualitatively enhanced beyond the barely detectable endogenous expression in untreated animals. Based on these promising studies, this CFTR minigene construct is a therapeutic candidate.
Highly Branched Poly Β-Amino Ester/cpg-Depleted CFTR Plasmid Nanoparticles for Non-viral Gene Therapy in Lung Cystic Fibrosis Disease

Bei Qiu,Dario Manzanares,Yinghao Li,Xianqing Wang,Zishan Li,Sebastien Terreau,Zhonglei He,Jing Lyu,Wenxin Wang,Irene Lara-Saez

DOI: https://doi.org/10.1016/j.omtm.2024.101292

2024-01-01

Abstract:Lung cystic fibrosis (CF) is a lethal inherited disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, leading to a dysfunctional CFTR protein. Gene therapy offers promise for the treatment of lung CF. However, the development and clinical application of CF gene therapy have long been hampered by the absence of safe and highly efficient delivery vectors. In this work, a novel polymer-based gene replacement treatment approach was developed. A series of poly (β-amino esters) (PAEs) with various topological structures and chemical compositions were screened to create non-viral therapeutic systems for CFTR restoration in lung CF disease. A nanoparticle, formed by the selected highly branched PAE (HPAE) with a CpG-depleted CFTR plasmid, demonstrated CFTR gene expression and biocompatibility in lung epithelial cells, outperforming leading commercial gene transfection reagents such as Lipofectamine 3000 and Xfect. The newly developed gene therapy system successfully restored functional CFTR protein production in lung CF epithelial monolayers. This therapeutic approach holds great potential for use as an efficient and safe non-viral treatment for CF patients.
A novel gene delivery method transduces porcine pancreatic duct epithelial cells

M A Griffin,M S Restrepo,M Abu-El-Haija,T Wallen,E Buchanan,T Rokhlina,Y H Chen,P B McCray,B L Davidson,A Divekar,A Uc

DOI: https://doi.org/10.1038/gt.2013.62

2013-11-21

Gene Therapy

Abstract:Gene therapy offers the possibility to treat pancreatic disease in cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR) gene; however, gene transfer to the pancreas is untested in humans. The pancreatic disease phenotype is very similar between humans and pigs with CF; thus, CF pigs create an excellent opportunity to study gene transfer to the pancreas. There are no studies showing efficient transduction of pig pancreas with gene-transfer vectors. Our objective is to develop a safe and efficient method to transduce wild-type (WT) porcine pancreatic ducts that express CFTR. We catheterized the umbilical artery of WT newborn pigs and delivered an adeno-associated virus serotype 9 vector expressing green-fluorescent protein (AAV9CMV.sceGFP) or vehicle to the celiac artery, the vessel that supplies major branches to the pancreas. This technique resulted in stable and dose-dependent transduction of pancreatic duct epithelial cells that expressed CFTR. Intravenous (IV) injection of AAV9CMV.sceGFP did not transduce the pancreas. Our technique offers an opportunity to deliver the CFTR gene to the pancreas of CF pigs. The celiac artery can be accessed via the umbilical artery in newborns and via the femoral artery at older ages—delivery approaches that can be translated to humans.

genetics & heredity,biochemistry & molecular biology,medicine, research & experimental,biotechnology & applied microbiology
318. Development of Optimized AAV Serotype Vectors for the Potential Gene Therapy of Cystic Fibrosis

Yanerys Colon-Cortes,Prativa Sharma,Chen Ling,Mutasim Abu-Hasan,Arun Srivastava,George Aslanidi

DOI: https://doi.org/10.1016/s1525-0016(16)33927-2

IF: 12.91

2015-01-01

Molecular Therapy

Abstract:Cystic fibrosis (CF) is a single gene mutation that it is estimated to affect 30,000 children and adults in the US, and 70,000 patients worldwide. The lack of a functional gene leads to a defective ion conductance, and the associated water transport abnormalities produce increased viscosity of secretions in exocrine epithelial cells. In the respiratory airways, mucus plugging and retention produces severe lung diseases making this the main cause of mortality among CF patients. Several groups have tried to correct this defect using recombinant AAV as a vector to carry the cystic fibrosis transmembrane conductance regulator (CFTR) gene to airway epithelial cells, but without success, mostly because of poor transduction efficiency of these cells. Although AAV vectors have been used successfully in animal models, and shown efficacy in several clinical trials, a number of steps in the life cycle of AAV, including intracellular trafficking, continue to appear to limit the effectiveness of these vectors in gene therapy. We have recently documented that the substitution of surface-exposed specific tyrosine (Y), serine (S), and threonine (T) residues on AAV capsids significantly increases the transduction efficiency of these vectors, both in vitro and in vivo, presumably by preventing phosphorylation, subsequent ubiquitination, and proteasome-mediated degradation. The current studies were undertaken to identify the optimal AAV serotype vectors with improved transduction efficiency in airway epithelial cells. First, we evaluated the transduction efficiency of several commonly used AAV serotype vectors in primary normal (CRL-40111) and CF donor-derived (CRL-4013) human airway epithelial cells. Our data indicated that AAV6 serotype vectors transduce both of these cell lines at high levels, followed by AAV2, AAV5, and AAV1. Interestingly, that transduction efficiency of AAV5 vectors, but not AAV1, 2, and 6, was higher in CRL-4013 cells compared with that in CRL-4011 cells. We have previously developed a number of single- and multiple-mutant capsid-optimized vectors for each serotype (18 for AAV1, 100 for AAV2, 15 for AAV5, and 35 for AAV6). Thus, we next evaluated the transduction efficiency of these capsid-optimized AAV serotype vectors in human airway epithelial cells. The result showed that mutations in a single serine (S) residue at position 663 for AAV1, 662 for AAV2, 651 for AAV5, and 663 for AAV6 to valine (V) increased the transduction efficiency 2-3-fold compared with the wild-type (WT) AAV vectors. Among the multiple-mutants, several beneficial combinations of Y and T residues were identified, such as AAV2-Y444-500-730F+T491V, AAV1-Y705-731F+T492V, AAV5-Y263+719F and AAV6-Y705-731F+T492V, which increased the transduction efficiency 3-5-fold compared with the WT-AAV vectors. Overall, the capsid-optimized AAV6 serotype was identified as the most efficient. Studies are currently underway to generate the optimized AAV6-CFTR vector for its use in the potential gene therapy for CF.
Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways

Patricia Cmielewski,Nigel Farrow,Sharnna Devereux,David Parsons,Martin Donnelley

DOI: https://doi.org/10.1080/01902148.2017.1395931

2017-11-26

Experimental Lung Research

Abstract:Purpose/Aim: Cystic fibrosis (CF) is the most common, fatal recessive genetic disease among the Caucasian population. Gene therapy has the potential to treat CF long term, however physiological barriers can prevent VSV-G pseudotyped lentiviral (LV) vectors from efficiently accessing the relevant receptors on the basolateral membrane of airway epithelial cells. The aims of this experiment were to use our new dose delivery techniques to determine whether conditioning the mouse lung conducting airways with lysophosphatidylcholine (LPC) improves the level of airway gene expression.MATERIALS AND METHODS: Anaesthetised normal C57Bl/6 mice were intubated with an endotracheal cannula to non-invasively facilitate airway access. The airways were conditioned with 0.1% LPC, 0.3% LPC, or PBS (control) instilled via the ET tube. One hour later a VSV-G pseudotyped LV vector carrying the LacZ transgene was delivered. LacZ expression was measured by X-gal staining of the excised lungs 3 months after gene delivery.RESULTS: Endotracheal intubation enabled precise dose delivery to the trachea and conducting airways. The cartilaginous airways of the groups conditioned with 0.1% and 0.3% LPC contained significantly larger numbers of LacZ positive cells compared to the PBS control group. In the LPC conditioned groups the majority of cell transduction was in ciliated epithelial cells.CONCLUSION: LPC conditioning prior to LV vector delivery, substantially enhanced the level of conducting airway gene expression after a single gene vector delivery. These results extend the previously established effectiveness of this protocol for producing gene expression in the nasal airways to the lung airways, the primary site of deleterious pathophysiology in CF individuals.

respiratory system
Lentiviral vector gene therapy and CFTR modulators show comparable effectiveness in cystic fibrosis rat airway models

Alexandra McCarron,Kak-Ming Ling,Samuel T. Montgomery,Kelly M. Martinovich,Patricia Cmielewski,Nathan Rout-Pitt,Anthony Kicic,David Parsons,Martin Donnelley

DOI: https://doi.org/10.1038/s41434-024-00480-y

2024-08-27

Gene Therapy

Abstract:Mutation-agnostic treatments such as airway gene therapy have the potential to treat any individual with cystic fibrosis (CF), irrespective of their CF transmembrane conductance regulator ( CFTR ) gene variants. The aim of this study was to employ two CF rat models, Phe508del and CFTR knockout (KO), to assess the comparative effectiveness of CFTR modulators and lentiviral (LV) vector-mediated gene therapy. Cells were isolated from the tracheas of rats and used to establish air-liquid interface (ALI) cultures. Phe508del rat ALIs were treated with the modulator combination, elexacaftor-tezacaftor-ivacaftor (ETI), and separate groups of Phe508del and KO tracheal epithelial cells were treated with LV-CFTR followed by differentiation at ALI. Ussing chamber measurements were performed to assess CFTR function. ETI-treated Phe508del ALI cultures demonstrated CFTR function that was 59% of wild-type level, while gene-addition therapy restored Phe508del to 68% and KO to 47% of wild-type level, respectively. Our findings show that rat Phe508del-CFTR protein can be successfully rescued with ETI treatment, and that CFTR gene-addition therapy provides significant CFTR correction in Phe508del and KO ALI cultures to levels that were comparable to ETI. These findings highlight the potential of an LV vector-based gene therapy for the treatment of CF lung disease.

genetics & heredity,biochemistry & molecular biology,medicine, research & experimental,biotechnology & applied microbiology
Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments

William B. Guggino,Liudmila Cebotaru

DOI: https://doi.org/10.1080/14712598.2017.1347630

2017-07-06

Expert Opinion on Biological Therapy

Abstract:INTRODUCTION: Since the cystic fibrosis (CF) gene was discovered in 1989, researchers have worked to develop a gene therapy. One of the most promising and enduring vectors is the AAV, which has been shown to be safe. In particular, several clinical trials have been conducted with AAV serotype 2. All of them detected viral genomes, but identification of mRNA transduction was not consistent; clinical outcomes in Phase II studies were also inconsistent. The lack of a positive outcome has been attributed to a less-than-efficient viral infection by AAV2, a weak transgene promoter and the host immune response to the vector. Areas covered: Herein, the authors focus on AAV gene therapy for CF, evaluating past experience with this approach and identifying ways forward, based on the progress that has already been made in identifying and overcoming the limitations of AAV gene therapy. Expert opinion: Such progress makes it clear that this is an opportune time to push forward toward the development of a gene therapy for CF. Drugs to treat the basic defect in CF represent a remarkable advance but cannot treat a significant cohort of patients with rare mutations. Thus, there is a critical need to develop a gene therapy for those individuals.

medicine, research & experimental,biotechnology & applied microbiology
A Controlled Study of Adenoviral-Vector–Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis

Michael R. Knowles,Kathy W. Hohneker,Zhaoqing Zhou,John C. Olsen,Terry L. Noah,Ping-Chuan Hu,Margaret W. Leigh,John F. Engelhardt,Lloyd J. Edwards,Kim R. Jones,Mariann Grossman,James M. Wilson,Larry G. Johnson,Richard C. Boucher

DOI: https://doi.org/10.1056/nejm199509283331302

IF: 158.5

1995-09-28

New England Journal of Medicine

Abstract:BACKGROUND: Cystic fibrosis is a monogenic disease that deranges multiple systems of ion transport in the airways, culminating in chronic infection and destruction of the lung. The introduction of a normal copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the airway epithelium through gene transfer is an attractive approach to correcting the underlying defects in patients with cystic fibrosis. We tested the feasibility of gene therapy using adenoviral vectors in the nasal epithelium of such patients.METHODS: An adenoviral vector containing the normal CFTR complementary DNA in four logarithmically increasing doses (estimated multiplicity of infection, 1, 10, 100, and 1000), or vehicle alone, was administered in a randomized, blinded fashion to the nasal epithelium of 12 patients with cystic fibrosis. Gene transfer was quantitated by molecular techniques that detected the expression of CFTR messenger RNA and by functional measurements of transepithelial potential differences (PDs) to assess abnormalities of ion transport specific to cystic fibrosis. The safety of this treatment was monitored by nasal lavage and biopsy to assess inflammation and vector replication.RESULTS: The adenoviral vector was detected in nasal-lavage fluid by culture, the polymerase chain reaction (PCR), or both in a dose-dependent fashion for up to eight days after vector administration. There was molecular evidence of gene transfer by reverse-transcriptase PCR assays or in situ hybridization in five of six patients treated at the two highest doses. However, the percentage of epithelial cells transfected by the vector was very low (< 1 percent), and measurement of PD across the epithelium revealed no significant restoration of chloride transport or normalization of sodium transport. At the lower doses of vector, there were no toxic effects. However, at the highest dose there was mucosal inflammation in two of three patients.CONCLUSIONS: In patients with cystic fibrosis, adenoviral-vector-mediated transfer of the CFTR gene did not correct functional defects in nasal epithelium, and local inflammatory responses limited the dose of adenovirus that could be administered to overcome the inefficiency of gene transfer.

medicine, general & internal
Durable transgene expression and efficient re-administration after rAAV2.5T-mediated fCFTRΔR gene delivery to adult ferret lungs

Yinghua Tang,Mehrnoosh Ebadi,Junying Lei,Zehua Feng,Shahab Fakhari,Peipei Wu,Mark D. Smith,Maria P. Limberis,Roland Kolbeck,Katherine J. Excoffon,Ziying Yan,John F. Engelhardt

DOI: https://doi.org/10.1016/j.omtm.2024.101244

2024-03-30

Abstract:The dosing interval for effective rAAV-mediated gene therapy of cystic fibrosis lung disease remains unknown. Here we assessed the durability of rAAV2.5T-fCFTRΔR-mediated transgene expression and neutralizing antibody (NAb) responses in lungs of adult wild-type ferrets. Within the first 3-months following rAAV2.5T-fCFTRΔR delivery to the lung, CFTRΔR transgene expression declined ∼5.6-fold and then remained stable to 5-months at ∼26% the level of endogenous CFTR . rAAV NAbs in the plasma and bronchioalveolar lavage fluid (BALF) peaked at 21-days, coinciding with peak ELISpot T-cell responses to AAV capsid peptides, after which both responses declined and remained stable at 4- to 5-months post-dosing. Administration of reporter vector rAAV2.5T-gLuc (gaussia luciferase) at 5-months following rAAV2.5T-fCFTRΔR dosing gave rise to similar levels of gLuc expression in the BALF as observed in age-matched reporter-only controls, demonstrating residual BALF NAb were functionally insignificant. Notably, the second vector administration led to a 2.6-fold greater ELISpot T-cell response and an ∼2.3-fold decline in f CFTRΔR mRNA and vector genomes derived from the initial rAAV2.5T-fCFTRΔR administration, suggesting selective destruction of transduced cells from the first vector dose. These findings provide insights into humoral and cellular immune response to rAAV that may be useful for optimizing gene therapy to the CF lung.

medicine, research & experimental
Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic

Martin Donnelley,David W. Parsons

DOI: https://doi.org/10.3389/fphar.2018.01381

IF: 5.6

2018-11-27

Frontiers in Pharmacology

Abstract:Cystic fibrosis (CF) is a progressive, chronic and debilitating genetic disease caused by mutations in the CF Transmembrane-Conductance Regulator (CFTR) gene. Unrelenting airway disease begins in infancy and produces a steady deterioration in quality of life, ultimately leading to premature death. While life expectancy has improved, current treatments for CF are neither preventive nor curative. Since the discovery of CFTR the vision of correcting the underlying genetic defect - not just treating the symptoms - has been developed to where it is poised to become a transformative technology. Addition of a properly functioning CFTR gene into defective airway cells is the only biologically rational way to prevent or treat CF airway disease for all CFTR mutation classes. While new gene editing approaches hold exciting promise, airway gene-addition therapy remains the most encouraging therapeutic approach for CF. However, early work has not yet progressed to large-scale clinical trials. For clinical trials to begin in earnest the field must demonstrate that gene therapies are safe in CF lungs; can provide clear health benefits and alter the course of lung disease; can be repeatedly dosed to boost effect; and can be scaled effectively from small animal models into human-sized lungs. Demonstrating the durability of these effects demands relevant CF animal models and accurate and reliable techniques to measure benefit. In this review, illustrated with data from our own studies, we outline recent technological developments and discuss these key questions that we believe must be answered to progress CF airway gene-addition therapies to clinical trials.

pharmacology & pharmacy
Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Yan-Jie Li,Chong Chen,Ling-Yu Zeng,Jiang Cao,Kai-Lin Xu

2012-01-01

Abstract:Recently, gene therapy has been become a promising approach to cure hemophilia A, a most common recessive bleeding disease. The aim of this study was to determine the perspective of lentiviral vector in hemophilia A gene therapy in vitro and in NOD/SCID mice. Lentivirus transfer vector pXZ9/BDDFVIII containing human B-domain-deleted Factor VIII-IRES-eGFP coding sequence and mock control pXZ9 were constructed. Lentivirus was prepared by co-transfecting 3 plasmids into 293FT cells. 293FT, HLF, human bone marrow mesenchymal stem cells and Chang-liver cells were transfected with the prepared virus. Coagulant activity of human FVIII, human FVIII antigen, human FVIII mRNA transcription and genomic integration were assayed by ELISA, one-step method, RT-PCR and PCR after infection. Lentiviral particles were concentrated by ultracentrifugation and NOD/SCID mice were transfected via portal vein injection. Human FVIII antigen in mouse blood plasma was analyzed by ELISA. eGFP expression was observed by fluorescent microscopy and human FVIII transcription in mouse liver was analyzed by RT-PCR at one month after transduction. The results showed that the high titer of recombinant virus was prepared and used to efficiently transduce the target cells in vitro. At 72 h after transfection, high levels of FVIII activity and FVIII antigen were detected. Human FVIII gene transcription could be detected in the liver of NOD/SCID mice received lentiviral particles carrying FVIII gene. Mouse hepatocytes were transfected with recombinant lentivirus efficiently in vivo. Human FVIII level in mouse blood plasma reached to (49 ± 6) mU, (54 ± 8) mU and (23 ± 4) mU at 72 h, one week and one month after transfection respectively. It is concluded that the lentiviral particles carrying BDDhFVIII gene can high efficiently transfect the target cells both in vitro and in vivo, and the transfected target cells can secrete hFVIII efficiently. The sustained expression of human FVIII in NOD/SCID mice is observed after lentivirus transfection via portal vein injection.
Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

A K M Ashiqul Haque,Alexander Dewerth,Justin S Antony,Joachim Riethmüller,Georg R Schweizer,Petra Weinmann,Ngadhnjim Latifi,Hanzey Yasar,Nicoletta Pedemonte,Elvira Sondo,Brian Weidensee,Anjali Ralhan,Julie Laval,Patrick Schlegel,Christian Seitz,Brigitta Loretz,Claus-Michael Lehr,Rupert Handgretinger,Michael S D Kormann

DOI: https://doi.org/10.1038/s41598-018-34960-0

2018-11-13

Abstract:Gene therapy has always been a promising therapeutic approach for Cystic Fibrosis (CF). However, numerous trials using DNA or viral vectors encoding the correct protein resulted in a general low efficacy. In the last years, chemically modified messenger RNA (cmRNA) has been proven to be a highly potent, pulmonary drug. Consequently, we first explored the expression, function and immunogenicity of human (h)CFTR encoded by cmRNAhCFTR in vitro and ex vivo, quantified the expression by flow cytometry, determined its function using a YFP based assay and checked the immune response in human whole blood. Similarly, we examined the function of cmRNAhCFTR in vivo after intratracheal (i.t.) or intravenous (i.v.) injection of the assembled cmRNAhCFTR together with Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) nanoparticles (NPs) by FlexiVent. The amount of expression of human hCFTR encoded by cmRNAhCFTR was quantified by hCFTR ELISA, and cmRNAhCFTR values were assessed by RT-qPCR. Thereby, we observed a significant improvement of lung function, especially in regards to FEV0.1, suggesting NP-cmRNAhCFTR as promising therapeutic option for CF patients independent of their CFTR genotype.
[Chemical degradation of 15 composites--an SEM study].

P. Städtler,M. Pabst

1991-05-01

Abstract:SEM-micrographs of 15 untreated composites that were laid in 96% ethanol were investigated. The surface of untreated samples show different fissures and cracks. Under the influence of alcohol the fissures become wider, the bond between fillers and unfilled resin enlarges, and the filling particles become prominent or fall out. Fine-grained hybrid composites with an unfilled resin densely compacted with microfillers, are least prone to degradation.
Effects of Technical Market Indicators on Stock Market Index Direction Forecasting

Günter Şenyurt,A. Subasi

DOI: https://doi.org/10.13187/mai.2015.6.137

Abstract:In this study, we examine and compare the performances of data mining techniques based on the daily indexes of five different markets, namely DAX, FTSE 100, NASDAQ Composite, NIKKEI 225 and NYSE Composite. The A/D oscillator, chaikin oscillator, moving average convergence/divergence, stochastic oscillator, acceleration, momentum, chaikin volatility, fast stochastics, slow stochastics, williams %R, negative volume index, positive volume index, relative strength index, accumulation/distribution line, bollinger band, highest high, lowest low, median price, on balance volume, price rate of change, price-volume trend, typical price, volume rate of change, weighted close and williams accumulation/distribution make up the 28 technical indicator attributes used in this study. The data mining techniques utilized in this study comprise of random forest model, artificial neural network (ANN) and support vector machine (SVM). Initially, the input features are sorted with WEKA’s Info Ranker which reveals the best attributes based on relative weight. Afterwards, ten attributes having the highest relative weight values are fed into random forest, ANN and SVM. Then different attribute combinations based on their relative weights are tested in turns for more precision.
Postnatal airway growth in cystic fibrosis piglets

Ryan J Adam,Mahmoud H Abou Alaiwa,Drake C Bouzek,Daniel P Cook,Nicholas D Gansemer,Peter J Taft,Linda S Powers,Mallory R Stroik,Mark J Hoegger,James D McMenimen,Eric A Hoffman,Joseph Zabner,Michael J Welsh,David K Meyerholz,David A Stoltz

DOI: https://doi.org/10.1152/japplphysiol.00263.2017

2017-09-01

Abstract:Mutations in the gene encoding the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) anion channel cause CF. The leading cause of death in the CF population is lung disease. Increasing evidence suggests that in utero airway development is CFTR-dependent and that developmental abnormalities may contribute to CF lung disease. However, relatively little is known about postnatal CF airway growth, largely because such studies are limited in humans. Therefore, we examined airway growth and lung volume in a porcine model of CF. We hypothesized that CF pigs would have abnormal postnatal airway growth. To test this hypothesis, we performed CT-based airway and lung volume measurements in 3-wk-old non-CF and CF pigs. We found that 3-wk-old CF pigs had tracheas of reduced caliber and irregular shape. Their bronchial lumens were reduced in size proximally but not distally, were irregularly shaped, and had reduced distensibility. Our data suggest that lack of CFTR results in aberrant postnatal airway growth and development, which could contribute to CF lung disease pathogenesis.NEW & NOTEWORTHY This CT scan-based study of airway morphometry in the cystic fibrosis (CF) postnatal period is unique, as analogous studies in humans are greatly limited for ethical and technical reasons. Findings such as reduced airway lumen area and irregular caliber suggest that airway growth and development are CF transmembrane conductance regulator-dependent and that airway growth defects may contribute to CF lung disease pathogenesis.
Investigating Adverse Genomic and Regulatory Changes Caused by Replacement of the Full-length CFTR cDNA Using Cas9 and AAV

Sriram Vaidyanathan,Jenny L. Kerschner,Alekh Paranjapye,Vrishti Sinha,Brian Lin,Tracy A. Bedrosian,Adrian J. Thrasher,Giandomenico Turchiano,Ann Harris,Matthew H. Porteus

DOI: https://doi.org/10.1016/j.omtn.2024.102134

IF: 10.183

2024-02-04

Molecular Therapy — Nucleic Acids

Abstract:A "Universal strategy" replacing the full-length CFTR cDNA may treat >99% of people with cystic fibrosis (pwCF) regardless of their specific mutations. Cas9-based gene editing was used to insert the CFTR cDNA and a truncated CD19 ( tCD19 ) enrichment tag at the CFTR locus in airway basal stem cells. This strategy restores CFTR function to non-CF levels. Here, we investigate the safety of this approach by assessing genomic and regulatory changes after CFTR cDNA insertion. Safety was first assessed by quantifying genetic rearrangements using CAST-seq. After validating restored CFTR function in edited and enriched airway cells, the CFTR locus open chromatin profile was characterized using ATAC-seq. The regenerative potential and differential gene expression in edited cells was assessed using scRNA-seq. CAST-seq revealed a translocation in ∼0.01% of alleles primarily occurring at a non-oncogenic off-target site and large INDELs in 1% of alleles. The open chromatin profile of differentiated airway epithelial cells showed no appreciable changes except in the region corresponding to the CFTR cDNA and tCD19 cassette indicating no detectable changes in gene regulation. Edited stem cells produced the same types of airway cells as controls with minimal alternations in gene expression. Overall, the Universal strategy showed minor undesirable genomic changes.

medicine, research & experimental
Backbone cationized highly branched poly( β -amino ester)s as enhanced delivery vectors in non-viral gene therapy

Yinghao Li,Bei Qiu,Zishan Li,Xianqing Wang,Zhonglei He,Darío Manzanares Sandoval,Rijian Song,A. Sigen,Chunyu Zhao,Melissa Johnson,Jing Lyu,Irene Lara-Sáez,Wenxin Wang

DOI: https://doi.org/10.1016/j.jconrel.2024.01.046

IF: 11.467

2024-02-03

Journal of Controlled Release

Abstract:Gene therapy holds great potential for treating Lung Cystic Fibrosis (CF) which is a fatal hereditary condition arising from mutations in the CF transmembrane conductance regulator (CFTR) gene, resulting in dysfunctional CFTR protein. However, the advancement and clinical application of CF gene therapy systems have been hindered due to the absence of a highly efficient delivery vector. In this work, we introduce a new generation of highly branched poly( β -amino ester) (HPAE) gene delivery vectors for CF treatment. Building upon the classical chemical composition of HPAE, a novel backbone cationization strategy was developed to incorporate additional functional amine groups into HPAE without altering their branching degree. By carefully adjusting the type, proportion, and backbone distribution of the added cationic groups, a series of highly effective HPAE gene delivery vectors were successfully constructed for CF disease gene therapy. In vitro assessment results showed that the backbone cationized HPAEs with randomly distributed 10% proportion of 1-(3-aminopropyl)-4-methylpiperazine (E7) amine groups exhibited superior transfection performance than their counterparts. Furthermore, the top-performed backbone cationized HPAEs, when loaded with therapeutic plasmids, successfully reinstated CFTR protein expression in the CFBE41o- disease model, achieving levels 20–23 times higher than that of normal human bronchial epithelial (HBE) cells. Their therapeutic effectiveness significantly surpassed that of the currently advanced commercial vectors, Xfect and Lipofectamine 3000.

pharmacology & pharmacy,chemistry, multidisciplinary
Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.

Hui Lu,Lingxia Chen,Jinhui Wang,Bernd Huack,Rita Sarkar,Shangzhen Zhou,Ray Xu,Qiulan Ding,Xuefeng Wang,Hongli Wang,Weidong Xiao

DOI: https://doi.org/10.1089/hum.2007.0182

2010-01-01

Human Gene Therapy

Abstract:Hemophilia A is caused by a deficiency in the factor VIII (FVIII) gene. Constrained by limited packaging capacity, even the 4.3-kb B domain-deleted FVIII remained a challenge for delivery by a single adeno-associated viral (AAV) vector. Studies have shown that up to a 6.6-kb vector sequence may be packaged into AAV virions, which suggested an alternative strategy for hemophilia A gene therapy. To explore the usefulness of AAV vectors carrying an oversized FVIII gene, we constructed the AAV-FVIII vector under the control of a P-actin promoter with a cytomegalovirus enhancer (CB) and a bovine growth hormone (bGH) poly(A) sequence. The CB promoter plus bGH signal was shown to be 3- to 5-fold more potent than the mini-transthyretin (TTR) promoter with a synthetic poly(A) sequence for directing FVIII expression in the liver. Despite the 5.75-kb genome size of pAAV-CB-FVIII, sufficient AAV vectors were produced for in vivo testing. Approximately 3- to 5-fold more FVIII secretion was observed in animals receiving AAV-CB-FVIII vectors than in those receiving Standard-sized AAV-TTR-FVIII vectors. Both the activated partial thromboplastin time assay and the whole blood thromboelastographic analysis confirmed that AAV-FVIII vectors fully corrected the bleeding phenotype of hemophilia mice. These results suggest that AAV vectors with an oversized genome should be useful for not only hemophilia A gene therapy but also other diseases with large cDNA such as muscular dystrophy and cystic fibrosis.

Current and past menstrual status is an important determinant of femoral neck geometry in exercising women.

CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

Expression of a Truncated Cystic Fibrosis Transmembrane Conductance Regulator with an AAV5-pseudotyped Vector in Primates

Highly Branched Poly Β-Amino Ester/cpg-Depleted CFTR Plasmid Nanoparticles for Non-viral Gene Therapy in Lung Cystic Fibrosis Disease

A novel gene delivery method transduces porcine pancreatic duct epithelial cells

318. Development of Optimized AAV Serotype Vectors for the Potential Gene Therapy of Cystic Fibrosis

Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways

Lentiviral vector gene therapy and CFTR modulators show comparable effectiveness in cystic fibrosis rat airway models

Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments

A Controlled Study of Adenoviral-Vector–Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis

Durable transgene expression and efficient re-administration after rAAV2.5T-mediated fCFTRΔR gene delivery to adult ferret lungs

Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

[Chemical degradation of 15 composites--an SEM study].

Effects of Technical Market Indicators on Stock Market Index Direction Forecasting

Postnatal airway growth in cystic fibrosis piglets

Investigating Adverse Genomic and Regulatory Changes Caused by Replacement of the Full-length CFTR cDNA Using Cas9 and AAV

Backbone cationized highly branched poly( β -amino ester)s as enhanced delivery vectors in non-viral gene therapy

Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.